Teva's Next Blockbuster? Its Anti-CGRP Antibody Prepares For Phase III In Difficult-To-Treat Migraines
This article was originally published in Scrip
Teva Pharmaceutical Industries confirmed it is to start Phase III studies with TEV-48125, its humanized monoclonal antibody against calcitonin-gene-related peptide (CGRP), but the company was not giving details on timings and indications as it published online Sept. 30 the full Phase IIb clinical trial results with the product in episodic migraine and chronic migraine, in two papers in The Lancet Neurology.
Register for our free email digests: